CO2018007271A2 - Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen - Google Patents

Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Info

Publication number
CO2018007271A2
CO2018007271A2 CONC2018/0007271A CO2018007271A CO2018007271A2 CO 2018007271 A2 CO2018007271 A2 CO 2018007271A2 CO 2018007271 A CO2018007271 A CO 2018007271A CO 2018007271 A2 CO2018007271 A2 CO 2018007271A2
Authority
CO
Colombia
Prior art keywords
azaphosphinans
phosphinanes
pharmaceutical compositions
preparation process
compositions containing
Prior art date
Application number
CONC2018/0007271A
Other languages
English (en)
Spanish (es)
Inventor
Philippe Gloanec
Arnaud-Pierre Schaffner
Patricia Sansilvestri-Morel
Alain Rupin
Philippe Mennecier
Marie-Odile Vallez
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55752640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018007271(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CO2018007271A2 publication Critical patent/CO2018007271A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CONC2018/0007271A 2016-01-14 2018-07-12 Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen CO2018007271A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1670004A FR3046793B1 (fr) 2016-01-14 2016-01-14 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2017/050075 WO2017121969A1 (fr) 2016-01-14 2017-01-13 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CO2018007271A2 true CO2018007271A2 (es) 2018-07-19

Family

ID=55752640

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007271A CO2018007271A2 (es) 2016-01-14 2018-07-12 Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Country Status (47)

Country Link
US (2) US10138260B2 (enExample)
EP (1) EP3271368B1 (enExample)
JP (1) JP2019504070A (enExample)
KR (1) KR20180101522A (enExample)
CN (1) CN108495857A (enExample)
AR (1) AR107433A1 (enExample)
AU (1) AU2017207003B2 (enExample)
BR (1) BR112018014020A2 (enExample)
CA (1) CA3011184C (enExample)
CL (1) CL2018001862A1 (enExample)
CO (1) CO2018007271A2 (enExample)
CU (1) CU20180072A7 (enExample)
CY (1) CY1121154T1 (enExample)
DK (1) DK3271368T3 (enExample)
DO (1) DOP2018000165A (enExample)
EA (1) EA035072B1 (enExample)
EC (1) ECSP18051972A (enExample)
ES (1) ES2709376T3 (enExample)
FR (1) FR3046793B1 (enExample)
GE (1) GEP20207092B (enExample)
HK (1) HK1244283B (enExample)
HR (1) HRP20190193T1 (enExample)
HU (1) HUE042924T2 (enExample)
IL (1) IL260425B (enExample)
JO (1) JO3660B1 (enExample)
LT (1) LT3271368T (enExample)
MA (1) MA41798B1 (enExample)
MD (1) MD3271368T2 (enExample)
ME (1) ME03305B (enExample)
MX (1) MX367319B (enExample)
NI (1) NI201800073A (enExample)
PE (1) PE20181503A1 (enExample)
PH (1) PH12018501373A1 (enExample)
PL (1) PL3271368T3 (enExample)
PT (1) PT3271368T (enExample)
RS (1) RS58338B1 (enExample)
RU (1) RU2729641C2 (enExample)
SG (1) SG11201805757WA (enExample)
SI (1) SI3271368T1 (enExample)
SV (1) SV2018005721A (enExample)
TN (1) TN2018000226A1 (enExample)
TR (1) TR201820430T4 (enExample)
TW (1) TWI625334B (enExample)
UA (1) UA121275C2 (enExample)
UY (1) UY37072A (enExample)
WO (1) WO2017121969A1 (enExample)
ZA (1) ZA201804391B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001425A (es) * 2000-08-17 2003-06-06 Pfizer Compuestos farmaceuticos.
SE0103272D0 (sv) * 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
AU2002249275A1 (en) * 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
US7420000B2 (en) * 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050143349A1 (en) * 2003-12-17 2005-06-30 Quatrx Pharmaceuticals Co. Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels
EP1874322A1 (en) * 2005-04-18 2008-01-09 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
US8367706B2 (en) * 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112012005438A2 (pt) * 2009-09-09 2018-03-20 Gilead Sciences Inc inibidores de vírus flaviviridae
MX2015000830A (es) * 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenosos y su aplicacion en farmacos.
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
SV2018005721A (es) 2018-09-06
EA201891599A1 (ru) 2019-01-31
TN2018000226A1 (fr) 2019-10-04
JO3660B1 (ar) 2020-08-27
ES2709376T3 (es) 2019-04-16
US10138260B2 (en) 2018-11-27
FR3046793B1 (fr) 2018-01-05
WO2017121969A1 (fr) 2017-07-20
CA3011184A1 (fr) 2017-07-20
CL2018001862A1 (es) 2018-10-05
US10654878B2 (en) 2020-05-19
DOP2018000165A (es) 2018-09-15
FR3046793A1 (fr) 2017-07-21
CN108495857A (zh) 2018-09-04
MX2018008639A (es) 2018-11-19
AU2017207003B2 (en) 2020-10-08
PE20181503A1 (es) 2018-09-18
SG11201805757WA (en) 2018-08-30
PL3271368T3 (pl) 2019-04-30
AU2017207003A1 (en) 2018-07-26
ECSP18051972A (es) 2018-07-31
RU2729641C2 (ru) 2020-08-11
UA121275C2 (uk) 2020-04-27
UY37072A (es) 2017-07-31
MA41798B1 (fr) 2018-11-30
RU2018129027A (ru) 2020-02-14
TW201726697A (zh) 2017-08-01
RS58338B1 (sr) 2019-03-29
HK1244283B (zh) 2019-11-22
KR20180101522A (ko) 2018-09-12
AR107433A1 (es) 2018-05-02
PH12018501373B1 (en) 2019-02-27
EP3271368A1 (fr) 2018-01-24
US20180016288A1 (en) 2018-01-18
RU2018129027A3 (enExample) 2020-03-19
BR112018014020A2 (pt) 2018-12-11
ME03305B (me) 2019-10-20
PH12018501373A1 (en) 2019-02-27
MX367319B (es) 2019-08-15
MA41798A (fr) 2018-01-24
LT3271368T (lt) 2018-12-10
AU2017207003A2 (en) 2018-10-04
GEP20207092B (en) 2020-04-10
US20190031693A1 (en) 2019-01-31
IL260425B (en) 2020-05-31
HRP20190193T1 (hr) 2019-04-05
SI3271368T1 (sl) 2019-02-28
DK3271368T3 (da) 2019-02-25
NI201800073A (es) 2018-09-06
TWI625334B (zh) 2018-06-01
CA3011184C (fr) 2020-09-29
HUE042924T2 (hu) 2019-07-29
MD3271368T2 (ro) 2019-03-31
TR201820430T4 (tr) 2019-01-21
EP3271368B1 (fr) 2018-10-31
ZA201804391B (en) 2020-01-29
JP2019504070A (ja) 2019-02-14
EA035072B1 (ru) 2020-04-23
CY1121154T1 (el) 2020-05-29
CU20180072A7 (es) 2018-10-04
PT3271368T (pt) 2018-12-04

Similar Documents

Publication Publication Date Title
MX340060B (es) Nuevos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol, su proceso de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de met.
BR112016026205A8 (pt) moduladores de entrançamento de gene smn2, seu uso e seu processo de preparação, e composições farmacêuticas
CR20160291A (es) Análogos de cortistatina y síntesis y usos de los mismos
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CO6331467A2 (es) Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2018013210A2 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY30859A1 (es) Nuevos derivados de 2-anilino-4-heteroarilpirimidinas , su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY30857A1 (es) Nuevos derivados de n,n'-2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
CR20110680A (es) Sulfonamidas heterociclicas, usos y composiciones farmacéuticas de las mismas
CO6331463A2 (es) Nuevos derivados de triazolo(4,3-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
MX2019013639A (es) Derivados de indol n-sustituidos.
ECSP13012838A (es) Nuevos compuestos de benzodioxol-piperazina
MX2017013101A (es) Piridopirimidinonas y utilizacion de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda).
CO6420339A2 (es) Derivados de 6-(6-sustituido-triazolopiridacina-sulfanil) 5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met
CO2018007271A2 (es) Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP12012329A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmacéuticas que la contienen
AR061740A1 (es) Nuevos derivados naftalenicos, su procedimiento de praparacion y las composiciones farmaceuticas que los contienen
AR061741A1 (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY33927A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EP4236915A4 (en) ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF ISOTRETINOIN